2021
Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC).
Dinan M, Wilson L, Greiner M, Spees L, Pritchard J, Zhang T, Kaye D, George D, Scales C, Wheeler S. Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 280-280. DOI: 10.1200/jco.2021.39.6_suppl.280.Peer-Reviewed Original ResearchMetastatic renal cell carcinomaOral anticancer agentsDisease-specific survivalRenal cell carcinomaCell carcinomaPatient populationSEER-Medicare patientsDisease-specific mortalityNumber of comorbiditiesOlder patient populationProgression-free survivalReal-world adherenceRandomized clinical trialsTreatment of patientsAnalysis of patientsProportion of daysRCC-specific mortalityMinimum effective doseSignificant reductionOAA therapyCause mortalityElderly patientsFavorable survivalMetastatic RCCMultivariable analysis
2013
Risk of Acute Thromboembolic Events With Oral Contraceptive Use
Urrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, Hasselblad V, Sanders GD, Myers ER. Risk of Acute Thromboembolic Events With Oral Contraceptive Use. Obstetrics And Gynecology 2013, 122: 380-389. PMID: 23969809, DOI: 10.1097/aog.0b013e3182994c43.Peer-Reviewed Original ResearchConceptsOral contraceptive pillsVenous thromboembolismMyocardial infarctionIschemic strokeHemorrhagic strokeOdds ratioCombined oral contraceptive pillAcute thromboembolic eventsOral contraceptive useRandomized clinical trialsSummary odds ratiosThromboembolic eventsCochrane DatabaseContraceptive pillsOCP useOCP usersClinical trialsSTUDY SELECTIONInclusion criteriaContraceptive useThromboembolismDiscordant decisionsSystematic reviewStrokeTeam review